← Back to Search

Teriparatide for Broken Bones

Phase 4
Waitlist Available
Led By Peter H. Edwards, Jr., MD
Research Sponsored by Ohio Orthopedic Center of Excellence
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 4 through 24 after start of treatment
Awards & highlights

Study Summary

This randomized, placebo-controlled study will evaluate the effectiveness of the adjunctive use of teriparatide for the healing of Jones fractures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 4 through 24 after start of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 4 through 24 after start of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Fracture healing
Secondary outcome measures
Function
Pain
Range of Motion
+1 more

Side effects data

From 2022 Phase 4 trial • 37 Patients • NCT04026256
44%
joint pain
22%
nausea
22%
propagation of fracture at biopsy site
11%
dizziness
11%
rhinorrhea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Denosumab Only
Teriparatide Only
Denosumab and Teriparatide

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TeriparatideExperimental Treatment1 Intervention
Patients randomized into this group will inject 20mcg of teriparatide once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
Group II: Placebo ControlPlacebo Group1 Intervention
Patients randomized into this group will inject a matching dose of placebo once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Teriparatide
FDA approved

Find a Location

Who is running the clinical trial?

Ohio Orthopedic Center of ExcellenceLead Sponsor
Eli Lilly and CompanyIndustry Sponsor
2,618 Previous Clinical Trials
3,201,522 Total Patients Enrolled
Peter H. Edwards, Jr., MDPrincipal InvestigatorOhio Orthopedic Center of Excellence

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures
2010. "The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01173081.
All > Forteo
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top